Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3029544 | Thrombosis Research | 2008 | 8 Pages |
Abstract
APC inhibited the stimulated expression of sPLA2-IIA in HASMC dose-dependently (1-300 nM). At the same time, APC increased the phosphorylation of ERK 1/2 and decreased NF-κB and C/EBP-β DNA-binding activities in these cells, as compared with respective stimulated controls. Reverse transcriptase-polymerase chain reaction and cell-based ELISA reveal an endothelial protein C receptor (EPCR) expression in HASMC. Application of antibodies against EPCR and protease-activated receptor-1 (PAR-1) reduced the APC-induced ERK 1/2 activation and the treatment of cells with a PAR-1 antagonist diminished the sPLA2-IIA inhibition. The obtained results show that APC effectively suppresses the up-regulated sPLA2-IIA expression, which might contribute to the reported beneficial effects of APC in the treatment of severe inflammatory disorders.
Keywords
RT-PCREPCRIFN-γERK 1/2FCSAPCHCAECHRPPAR-1HASMCPBSsPLA2-IIANF-κBBSAC/EBPDMSOenzyme-linked immunoassaybovine serum albuminhorse-radish peroxidaseSecretory phospholipase A2interferon-γELISADimethyl sulfoxidefetal calf serumhuman coronary artery endothelial cellshuman aortic smooth muscle cellsnuclear factor-κBMEKPhosphate-buffered salineReverse transcriptase-polymerase chain reactionpolymerase chain reactionPCRActivated protein Cmitogen-activated protein kinaseextracellular signal-regulated kinaseprotease-activated receptorsProtease-activated receptor-1endothelial protein C receptor
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Mario Menschikowski, Albert Hagelgans, Ute Hempel, Peter Lattke, Iskander Ismailov, Gabriele Siegert,